Changchun Bcht Biotechnology Co. Class ASSE: 688276

"Changchun Bcht Biotechnology Co."Announcement on Voluntary Disclosure Regarding the Acceptance of the Clinical Trial Application for the Combination Formulation of Recombinant Human Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibody Injection

· Issued by Changchun Bcht Biotechnology Co. Class A via Shanghai Stock Exchange

Filed with SSE ·

Announcement on Voluntary Disclosure Regarding the Acceptance of the Clinical Trial Application for the Combination Formulation of Recombinant Human Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibody Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Changchun Bcht Biotechnology Co. Class A

All Changchun Bcht Biotechnology Co. Class A news releases